Patents Assigned to Xencor
  • METHODS OF PURIFYING HETERODIMERIC PROTEINS USING IMMUNOGLOBULIN CLASS SWITCHING
    Publication number: 20140356381
    Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 4, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, John Desjarlais
  • Immunoglobulins insertions, deletions, and substitutions
    Patent number: 8883147
    Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: November 11, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Bassil Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • Fc variants with altered binding to FcRn
    Patent number: 8883973
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: November 11, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20140322217
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Application
    Filed: January 14, 2014
    Publication date: October 30, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory MOORE, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Optimized Fc variants and methods for their generation
    Patent number: 8858937
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: October 14, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • OPTIMIZED ANTI-CD3 VARIABLE REGIONS
    Publication number: 20140302064
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Application
    Filed: March 7, 2014
    Publication date: October 9, 2014
    Applicant: Xencor, Inc.
    Inventor: Gregory Moore
  • Fc variants with altered binding to FcRn
    Patent number: 8852586
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: October 7, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • HETERODIMERIC PROTEINS
    Publication number: 20140294823
    Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.
    Type: Application
    Filed: March 7, 2014
    Publication date: October 2, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Moore, Rumana Rashid, John Desjarlais
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20140294835
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 2, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • FC VARIANTS THAT IMPROVE FCRN BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
    Publication number: 20140294812
    Abstract: The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 2, 2014
    Applicant: Xencor, Inc.
    Inventor: Gregory Alan Lazar
  • TARGETING REGULATORY T CELLS WITH HETERODIMERIC PROTEINS
    Publication number: 20140294836
    Abstract: The present invention provides methods and compositions comprising a heterodimeric antibody comprising a first monomer comprising a first variant heavy chain constant region and an anti-CD4 binding moiety. The heterodimeric antibody also comprises a second monomer comprising: a second variant heavy chain constant region and an anti-CD25 binding moiety. In some cases, the pIs of the first and second variant heavy chain constant regions are at least 0.5 logs apart.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 2, 2014
    Applicant: Xencor, Inc.
    Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachchi
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20140288275
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 25, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS
    Publication number: 20140249297
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: January 27, 2014
    Publication date: September 4, 2014
    Applicant: XENCOR, INC.
    Inventors: Gregory A. LAZAR, Bassil I. DAHIYAT, Matthew J. BERNETT
  • Optimized Fc variants and methods for their generation
    Patent number: 8809503
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: August 19, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Fc variants with altered binding to FcRn
    Patent number: 8802820
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 12, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John Rudolph Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Optimized Fc variants
    Patent number: 8802823
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: August 12, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES
    Publication number: 20140212435
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 31, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory L. Moore, John Desjarlais
  • OPTIMIZED ANTIBODIES THAT TARGET HM1.24
    Publication number: 20140205605
    Abstract: The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.
    Type: Application
    Filed: March 11, 2013
    Publication date: July 24, 2014
    Applicant: XENCOR, INC.
    Inventor: XENCOR, INC.
  • Optimized Fc variants
    Patent number: 8753628
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: June 17, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Fc variants
    Patent number: 8753629
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: June 17, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter